Renub Research has recently published a report titled "Osteoporosis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2030." The report provides a detailed industry analysis, including market share insights, a study of competitors and regions, and recent growth in the Osteoporosis Drugs Market.
The osteoporosis drug market is predicted to grow significantly during 2022 and 2030, with a CAGR of 3.98%
An extremely high rate of morbidity and mortality is linked to osteoporosis, a common chronic metabolic bone disease. Osteoporosis is a significant global health issue that causes 8.9 million fractures each year, as well as poorer physical and mental health, lower life quality, and shorter life expectancy. A parallel rise in the incidence of fragility fractures will be seen as osteoporosis prevalence rises with aging. Fragility fractures are those that commonly develop at the vertebrae, wrist, hip, and pelvis after low-energy transfer trauma, such as falling from a standing height. The majority of fractures caused by osteoporosis and the resulting morbidity and mortality affect octogenarians and nonagenarians.
As getting older, bones undergo a natural process of bone loss. However, specific medical conditions can hinder one's ability to achieve maximum adult bone mass, which ultimately increases the risk of developing osteoporosis and experiencing bone fractures in later years. Primary osteoporosis is classified into two types - age-related and postmenopausal. Women are more susceptible to primary osteoporosis due to their lower peak bone mineral density compared to men. The postmenopausal decline in estrogen further increases this risk. Due to increased awareness, an aging population, diagnosis of osteoporosis, advanced drug therapies, and growing demand for preventive measures to address bone health issues, the Osteoporosis Drug Market is expected to reach US$ 17.52 Billion in 2030.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=global-osteoporosis-market-patients-companies-and-forecast-483-p.php
Osteoporosis can be brought on by or exacerbated by a wide range of illnesses, medications, and toxic substances. Secondary osteoporosis is a type of disease that, if identified as a potential threat, is frequently preventable through healthy eating habits and regular exercise, as well as with the help of appropriate therapy if required. Certain medical conditions, such as celiac disease, inflammatory bowel disease, kidney or liver disease, cancer, multiple myeloma, and rheumatoid arthritis, increase the risk of osteoporosis in a person.
Branded products dominate the osteoporosis drugs market
Branded osteoporosis medications dominate the market due to their exclusive patents, higher costs, and increased R&D spending. Effective marketing campaigns and patient brand loyalty also add to their notoriety. Branded medications also make it easier for patients to follow their treatment plans, which helps. However, the market share of generic osteoporosis medications is growing due to healthcare regulations and increasing patient and provider awareness of the advantages of generic alternatives.
Type – Osteoporosis Drugs Market has been covered from 2 viewpoints:
1. Branded
2. Generic
Bisphosphonates hold a leading position in the osteoporosis drug market
Bisphosphonates are the most popular medications for treating osteoporosis. They effectively reduce the risk of fractures by inhibiting osteoclast activity and stopping bone loss. They are more cost-effective than other osteoporosis drugs as they remain in the body longer.
Drug Class – Osteoporosis Drug Market has been covered from 6 viewpoints
1. Bisphosphonates
2. Selective Estrogen Inhibitors Modulator (SERM)
3. Parathyroid Hormone Therapy
4. Calcitonin
5. Rank Ligand Inhibitors
6. Others
In the osteoporosis drug market, oral medications command the largest market share
Oral medications dominate the osteoporosis drug market because they are convenient, equally effective as other administration methods, safe, and economical. Patients who receive their medications orally avoid the inconvenience or waiting times related to injections or infusions. They are both equally effective at treating osteoporosis and represent a good alternative due to how generally secure and tolerable they are. Another benefit of oral medications is that they are more reasonably priced. Patients' and doctors' preference for the convenience of oral medications further boosts their market share. Their status as safe and effective osteoporosis treatments is supported by the regulatory approval of the majority of countries.
Route of Administration – Global Osteoporosis Drugs Market has been covered from 3 viewpoints
1. Oral
2. Injectable
3. Others
The osteoporosis drug market is seeing rapid growth among online pharmacies
Patients can now order their medication online and deliver it to their homes without visiting a physical pharmacy. Online pharmacies have lower overhead expenses, which can reduce medication costs. Patients who might feel awkward discussing their condition in person may find comfort in the privacy of online transactions. Online pharmacies also give patients in remote areas or with transportation issues access. Moreover, they provide patients with valuable educational resources for information on osteoporosis and associated medications.
Distribution Channel – The Osteoporosis Drugs Market has been covered from 3 viewpoints
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
The United States holds the majority of the market share for drugs to treat osteoporosis due to the disease's high prevalence
The United States has a higher prevalence of osteoporosis, attributed to an aging population, increasing obesity rates, and decreased physical activity. The general public and medical professionals know about osteoporosis thanks to media attention and patient advocacy initiatives. Furthermore, the US has high reimbursement rates for osteoporosis drugs, ensuring better patient affordability. The sizeable market in the nation offers significant potential for drug sales. New osteoporosis medications are constantly being developed due to the presence of top pharmaceutical companies with a strong focus on research and development. Market share is also supported by easy access to health insurance and top-notch medical care. Last but not least, a supportive regulatory climate encourages pharmaceutical companies to spend money on the creation and promotion of osteoporosis medications.
Countries – The Osteoporosis Drugs Market has been covered from 26 viewpoints:
- United States
- Canada
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Malaysia
- Indonesia
- New Zealand
- Brazil
- Mexico
- Argentina
- South Africa
- Saudi Arabia
- Turkey
- UAE
- ROW
Competitive Landscape
Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Novartis International AG, Merck & Co. Inc., and Amgen Inc. are among the companies that are active in the osteoporosis drugs market.
Related Reports
Diabetes Drugs Market: https://www.renub.com/diabetes-drug-market-p.php
Schizophrenia Drugs Market: https://www.renub.com/schizophrenia-drugs-market-p.php
Rheumatoid Arthritis Drugs Market: https://www.renub.com/rheumatoid-arthritis-drugs-market-p.php
Personalized Medicine Market: https://t.ly/TY3RV
Company Insights
- Overview
- Recent Development
- Financial Insight
Top Osteoporosis Drugs Companies Analysis
1. Eli Lilly and Company
2. Pfizer Inc.
3. F. Hoffmann-La Roche
4. Teva Pharmaceutical Industries Ltd.
5. GlaxoSmithKline plc.
6. Novartis International AG
7. Merck & Co. Inc.
8. Amgen Inc.
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9500 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: info@renub.com
LinkedIn: https://linkedin.com/company/renub-research
Website: www.renub.com
